Silverarc Capital Management 13F annual report
Silverarc Capital Management is an investment fund managing more than $405 billion ran by Andrew Timpson. There are currently 65 companies in Mr. Timpson’s portfolio. The largest investments include Merus N.V and Nuvalent Inc, together worth $72.2 billion.
$405 billion Assets Under Management (AUM)
As of 7th August 2024, Silverarc Capital Management’s top holding is 623,628 shares of Merus N.V currently worth over $36.9 billion and making up 9.1% of the portfolio value.
Relative to the number of outstanding shares of Merus N.V, Silverarc Capital Management owns more than approximately 0.1% of the company.
In addition, the fund holds 465,710 shares of Nuvalent Inc worth $35.3 billion.
The third-largest holding is Avidity Biosciences worth $21.1 billion and the next is UroGen Pharma Ltd worth $18.5 billion, with 1,102,000 shares owned.
Currently, Silverarc Capital Management's portfolio is worth at least $405 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Silverarc Capital Management
The Silverarc Capital Management office and employees reside in Boston, Massachusetts. According to the last 13-F report filed with the SEC, Andrew Timpson serves as the CHIEF COMPLIANCE OFFICER at Silverarc Capital Management.
Recent trades
In the most recent 13F filing, Silverarc Capital Management revealed that it had opened a new position in
Nuvalent Inc and bought 465,710 shares worth $35.3 billion.
The investment fund also strengthened its position in Merus N.V by buying
123,628 additional shares.
This makes their stake in Merus N.V total 623,628 shares worth $36.9 billion.
Merus N.V soared 120.9% in the past year.
On the other hand, there are companies that Silverarc Capital Management is getting rid of from its portfolio.
Silverarc Capital Management closed its position in Immunogen on 14th August 2024.
It sold the previously owned 1,307,435 shares for $20.7 billion.
Andrew Timpson also disclosed a decreased stake in Morphic Hldg Inc by 0.2%.
This leaves the value of the investment at $16.6 billion and 486,306 shares.
One of the smaller hedge funds
The two most similar investment funds to Silverarc Capital Management are Kozak & Associates and Marino, Stram & Associates. They manage $405 billion and $405 billion respectively.
Andrew Timpson investment strategy
Silverarc Capital Management’s portfolio is diversified across 3 sectors.
Currently, their heaviest sector is Health Care — making up 70.6% of
the total portfolio value.
The fund focuses on investments in the United States as
67.7% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
18% of the total holdings value.
On the other hand, large-cap stocks make up only 4.6% of the portfolio.
The average market cap of the portfolio companies is close to $2.29 billion.
The complete list of Silverarc Capital Management trades based on 13F SEC filings
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Merus N.V |
24.73%
623,628
|
$36,900,069,000 | 9.11% |
| Nuvalent Inc |
Opened
465,710
|
$35,328,761,000 | 8.72% |
| Avidity Biosciences, Inc. |
Opened
517,734
|
$21,149,434,000 | 5.22% |
| Immunogen, Inc. |
Closed
1,307,435
|
$20,748,993,000 | |
| UroGen Pharma Ltd |
116.55%
1,102,000
|
$18,491,560,000 | 4.57% |
| Erasca Inc |
Opened
7,816,926
|
$18,447,945,000 | 4.55% |
| Morphic Hldg Inc |
17.69%
486,306
|
$16,568,445,000 | 4.09% |
| Akero Therapeutics Inc |
1,894.79%
625,087
|
$14,664,541,000 | 3.62% |
| Celldex Therapeutics Inc. |
Opened
374,910
|
$13,875,419,000 | 3.43% |
| Intra-Cellular Therapies Inc |
7.85%
192,345
|
$13,173,709,000 | 3.25% |
| Poseida Therapeutics, Inc. |
1.12%
3,607,999
|
$10,535,357,000 | 2.60% |
| Cogent Biosciences, Inc. |
85.18%
1,206,214
|
$10,168,384,000 | 2.51% |
| Insmed Inc |
6.91%
140,000
|
$9,380,000,000 | 2.32% |
| Cymabay Therapeutics Inc |
Closed
590,000
|
$8,796,900,000 | |
| Alnylam Pharmaceuticals Inc |
Opened
36,000
|
$8,748,000,000 | 2.16% |
| Mirati Therapeutics Inc |
Closed
200,000
|
$8,712,000,000 | |
| Krystal Biotech Inc |
Closed
71,531
|
$8,297,596,000 | |
| Elutia Inc |
Opened
1,603,580
|
$7,953,757,000 | 1.96% |
| Corbus Pharmaceuticals Hldgs |
Opened
172,492
|
$7,805,263,000 | 1.93% |
| Oric Pharmaceuticals, Inc. |
4.23%
1,075,812
|
$7,605,991,000 | 1.88% |
| Syndax Pharmaceuticals Inc |
1,750.00%
370,000
|
$7,596,100,000 | 1.88% |
| Rhythm Pharmaceuticals Inc. |
29.12%
184,662
|
$7,582,222,000 | 1.87% |
| United Therapeutics Corp |
Closed
31,424
|
$7,097,739,000 | |
| Praxis Precision Medicines, Inc. |
Closed
4,117,920
|
$7,041,643,000 | |
| C4 Therapeutics, Inc. |
Opened
1,442,841
|
$6,665,925,000 | 1.65% |
| Sarepta Therapeutics Inc |
356.67%
42,000
|
$6,636,000,000 | 1.64% |
| KalVista Pharmaceuticals Inc |
145.00%
560,883
|
$6,607,202,000 | 1.63% |
| Crinetics Pharmaceuticals Inc |
Closed
220,000
|
$6,542,800,000 | |
| Veracyte Inc |
17.81%
282,248
|
$6,116,314,000 | 1.51% |
| Abivax Sa |
Opened
455,800
|
$6,025,676,000 | 1.49% |
| Olema Pharmaceuticals, Inc. |
34.10%
546,863
|
$5,917,058,000 | 1.46% |
| Biocryst Pharmaceuticals Inc. |
Closed
791,671
|
$5,605,031,000 | |
| ADC Therapeutics SA |
Opened
1,768,770
|
$5,589,313,000 | 1.38% |
| Novo Nordisk A/s |
Closed
60,000
|
$5,456,400,000 | |
| Helix Acquisition Corp Ii |
Opened
500,000
|
$5,110,000,000 | 1.26% |
| Mersana Therapeutics Inc |
49.99%
2,500,585
|
$5,026,176,000 | 1.24% |
| Gossamer Bio, Inc. |
10.28%
5,500,000
|
$4,954,950,000 | 1.22% |
| Humana Inc. |
Closed
10,000
|
$4,865,200,000 | |
| Vertex Pharmaceuticals, Inc. |
Closed
13,765
|
$4,786,641,000 | |
| Gilead Sciences, Inc. |
Closed
62,789
|
$4,705,408,000 | |
| TELA Bio, Inc. |
103.89%
1,000,000
|
$4,700,000,000 | 1.16% |
| Disc Medicine Inc |
Opened
101,187
|
$4,560,498,000 | 1.13% |
| Biogen Inc |
31.01%
19,365
|
$4,489,194,000 | 1.11% |
| Verona Pharma Plc |
Opened
304,633
|
$4,404,993,000 | 1.09% |
| Pliant Therapeutics, Inc. |
Closed
250,409
|
$4,342,092,000 | |
| Caribou Biosciences Inc |
Closed
892,786
|
$4,267,517,000 | |
| Geron Corp. |
Opened
999,270
|
$4,236,905,000 | 1.05% |
| Biohaven Ltd |
900.00%
100,000
|
$3,471,000,000 | 0.86% |
| Longboard Pharmaceuticals In |
Opened
122,849
|
$3,320,608,000 | 0.82% |
| Praxis Precision Medicines I |
Opened
67,296
|
$2,783,363,000 | 0.69% |
| Structure Therapeutics Inc |
Opened
70,516
|
$2,769,163,000 | 0.68% |
| Biodesix Inc |
Opened
1,808,959
|
$2,767,707,000 | 0.68% |
| Mirum Pharmaceuticals Inc |
28.08%
79,194
|
$2,707,643,000 | 0.67% |
| Solid Biosciences Inc |
Opened
472,995
|
$2,681,882,000 | 0.66% |
| Perspective Therapeutics Inc |
Opened
260,009
|
$2,592,290,000 | 0.64% |
| Cerus Corp. |
21.75%
1,465,744
|
$2,579,709,000 | 0.64% |
| Compugen Ltd |
328.66%
1,501,113
|
$2,521,870,000 | 0.62% |
| Trevi Therapeutics, Inc. |
8.97%
844,235
|
$2,515,820,000 | 0.62% |
| Terns Pharmaceuticals Inc |
Closed
500,000
|
$2,515,000,000 | |
| Kodiak Sciences Inc |
4.70%
1,062,062
|
$2,495,846,000 | 0.62% |
| Jasper Therapeutics Inc |
Opened
109,892
|
$2,494,548,000 | 0.62% |
| Engene Holdings Inc |
Opened
263,841
|
$2,488,021,000 | 0.61% |
| Wave Life Sciences Ltd. |
Opened
495,471
|
$2,472,400,000 | 0.61% |
| Fulcrum Therapeutics Inc |
Opened
398,436
|
$2,470,303,000 | 0.61% |
| Evogene Ltd |
0.65%
3,079,739
|
$2,003,062,000 | 0.49% |
| Stoke Therapeutics, Inc. |
Opened
141,518
|
$1,911,908,000 | 0.47% |
| Xenon Pharmaceuticals Inc |
Closed
53,996
|
$1,844,503,000 | |
| Intellia Therapeutics Inc |
Closed
53,018
|
$1,676,429,000 | |
| Macrogenics Inc |
70.73%
370,000
|
$1,572,500,000 | 0.39% |
| Modular Med Inc |
Opened
900,000
|
$1,422,000,000 | 0.35% |
| Aerovate Therapeutics Inc |
Closed
100,000
|
$1,357,000,000 | |
| Prothena Corporation plc |
Closed
26,629
|
$1,284,849,000 | |
| Roivant Sciences Ltd |
Closed
100,000
|
$1,168,000,000 | |
| Alkermes plc |
Closed
41,455
|
$1,161,155,000 | |
| Zura Bio Ltd |
18.70%
328,504
|
$1,149,764,000 | 0.28% |
| Tarsus Pharmaceuticals, Inc. |
Opened
40,000
|
$1,087,200,000 | 0.27% |
| Annexon Inc |
Closed
399,716
|
$943,330,000 | |
| VYNE Therapeutics Inc. |
Opened
467,397
|
$920,772,000 | 0.23% |
| Biomarin Pharmaceutical Inc. |
Closed
10,000
|
$884,800,000 | |
| Sagimet Biosciences Inc |
Closed
100,000
|
$880,000,000 | |
| EyePoint Pharmaceuticals Inc |
Opened
100,000
|
$870,000,000 | 0.21% |
| Schrodinger, Inc. |
Closed
30,311
|
$856,892,000 | |
| Voyager Therapeutics Inc |
Closed
103,966
|
$805,737,000 | |
| 89bio Inc |
53.20%
92,298
|
$739,307,000 | 0.18% |
| Viridian Therapeutics Inc |
Closed
47,438
|
$727,699,000 | |
| Molecular Templates Inc |
75.92%
623,838
|
$717,414,000 | 0.18% |
| Fractyl Health Inc |
Opened
166,666
|
$711,664,000 | 0.18% |
| Point Biopharma Global Inc |
Closed
93,700
|
$624,979,000 | |
| Soleno Therapeutics Inc |
95.95%
15,000
|
$612,000,000 | 0.15% |
| Rezolute Inc |
Closed
433,240
|
$571,877,000 | |
| Karyopharm Therapeutics Inc |
0.62%
558,466
|
$484,525,000 | 0.12% |
| Eliem Therapeutics Inc |
Closed
121,110
|
$318,519,000 | |
| Relmada Therapeutics Inc |
0.62%
99,379
|
$298,137,000 | 0.07% |
| Eloxx Pharmaceuticals Inc |
Closed
54,075
|
$260,101,000 | |
| Clene Inc |
Closed
500,000
|
$247,950,000 | |
| Aligos Therapeutics, Inc. |
3.74%
655,515
|
$229,430,000 | 0.06% |
| Vaxcyte, Inc. |
Opened
2,500
|
$188,775,000 | 0.05% |
| Scholar Rock Holding Corp |
Closed
9,711
|
$68,948,000 | |
| Rocket Pharmaceuticals Inc Wts |
Closed
104,828
|
$17,821,000 | |
| No transactions found | |||
| Showing first 500 out of 99 holdings | |||
Hedge funds similar to Silverarc Capital Management
- Cmh Wealth Management
- Flc Capital Advisors
- America First Investment Advisors
- Foyston, Gordon, & Payne Inc
- Jackson Square Capital
- Manchester Financial Inc
- Pbmares Wealth Management
- Kozak & Associates
- Marino, Stram & Associates
- Kula Investments
- Compass Wealth Management
- Liberty Wealth Management
- Elite Wealth Management
- Element Pointe Advisors